APTIVUS

This brand name is authorized in Austria, Australia, Canada, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland, United Kingdom, United States, South Africa

Active ingredients

The drug APTIVUS contains one active pharmaceutical ingredient (API):

1 Tipranavir UNII ZZT404XD09 - TIPRANAVIR

Tipranavir is a non-peptidic inhibitor of the HIV-1 protease that inhibits viral replication by preventing the maturation of viral particles. Read about Tipranavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
APTIVUS Soft capsules	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AE09	Tipranavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10344K
Country: CA	Health Products and Food Branch	Identifier(s): 02273322
Country: EE	Ravimiamet	Identifier(s): 1218833, 1423820
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 05315001
Country: FR	Base de données publique des médicaments	Identifier(s): 67219072, 68530375
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 97472
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1027444, 1050605
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100074662, 100308597
Country: US	FDA, National Drug Code	Identifier(s): 0597-0002, 0597-0003
Country: ZA	Health Products Regulatory Authority	Identifier(s): 43/20.2.8/0226